Medication classes
Antibiotic articles covering medicines such as metronidazole and ciprofloxacin when they appear in Crohn's disease and IBD care. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
17 articles
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...
Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...
This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
Anal fistulas are a common and often painful complication of Crohn’s disease that usually need medical or surgical treatment. Managing the underlying Crohn’s with biologic therapy is often necessary for fistulas to heal....
If your Crohn’s gets worse, your care plan may change — from new medicines to nutritional support or surgery — and this article summarizes common steps doctors take to prevent complications and control inflammation.
